Treating PCOS With Semaglutide vs Active Lifestyle Intervention
NCT03919929 on ClinicalTrials.gov · last registry update 2025-11-25
Finished 3 October 2023, after enrolling 60 people. Primary outcome, as filed: Change in Hepatic Fat Fraction. semaglutide is approved in the US, but not for mash nafld and pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2019-05-03
- Primary completion
- 2023-10-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Hepatic Fat Fraction
Conditions studied
PCOS · Adolescent Obesity · NAFLD
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.